MAA Laboratories — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

MAA Laboratories is a private, pre-revenue biotech company leveraging its proprietary NanoCont™ platform to reformulate existing drug molecules into next-generation therapies. The platform combines nanoparticle engineering with continuous manufacturing to enhance drug performance across multiple therapeutic areas, with a pipeline strategy focused on streamlined 505(b)(2) regulatory pathways. Led by an experienced team with deep pharmaceutical development and regulatory expertise, the company is advancing multiple programs with FDA-reviewed clinical strategies and is actively seeking partnerships to commercialize its technology.

OncologyPulmonary and fibrotic diseasesAutoimmune and inflammatory disordersNeurology and cardiovascular conditions

Technology Platform

NanoCont™ platform: a next-generation nanoparticle-based drug development and continuous manufacturing technology designed to improve drug bioavailability, reduce food-effect variability, enhance tolerability, and lower dose-related toxicity.

Opportunities

The 505(b)(2) pathway offers a faster, lower-risk route to market for improved formulations of existing drugs, with potential for new IP and exclusivity.

There is a large addressable market of suboptimal drugs across high-value therapeutic areas like oncology that could benefit from enhanced delivery.

The integration of continuous manufacturing aligns with regulatory priorities for modern, efficient production.

Risk Factors

Technical risk that the NanoCont™ platform fails to deliver consistent pharmacokinetic improvements in human trials.

Regulatory risk associated with the 505(b)(2) pathway and the novel continuous manufacturing process.

Financial risk as a pre-revenue company dependent on raising capital and securing partnerships to fund development.

Competitive Landscape

The drug reformulation and advanced delivery space is competitive, with numerous biotech and specialty pharma companies using lipid nanoparticles, polymers, and other technologies. MAA differentiates through the combination of nanoparticle formulation with integrated continuous manufacturing, aiming for both product superiority and scalable, cost-effective production.

More companies in Drug Delivery & Formulation →More companies in United States →